<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886702</url>
  </required_header>
  <id_info>
    <org_study_id>0453-01-01</org_study_id>
    <secondary_id>0453</secondary_id>
    <nct_id>NCT02886702</nct_id>
  </id_info>
  <brief_title>A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fougera Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fougera Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing
      Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a
      Vehicle Control in the Treatment of Stable Plaque Psoriasis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2016</start_date>
  <completion_date type="Actual">August 2, 2017</completion_date>
  <primary_completion_date type="Actual">August 2, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success Assessed by IGA</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of subjects with treatment success (defined as none, minimal or mild disease, a score of 0, 1 or 2 within the treatment area) on the &quot;Investigator's Global Assessment of Disease Severity&quot; (IGA) at the Week 12 visit (Day 85 ± 4 days, End of Study).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Severity None or Minimal on IGA</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of subjects with none or minimal disease, a score of 0 or 1 on the IGA at the Week 12 visit (Day 85 ± 4 days, End of Study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Site Plaque Elevation, Scaling and Erythema Scores of Less Than or Equal to 1 on the PASI</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of subjects with target site plaque elevation, scaling and erythema scores of less than or equal to 1 (Clear or Almost Clear) on the Psoriasis Area Severity Index (PASI) at the Week 12 visit (Day 85 ± 4 days, End of Study).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">855</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazarotene Cream 0.05%</intervention_name>
    <description>Tazarotene Cream 0.05% to cover only the lesions with a thin film.</description>
    <arm_group_label>Test</arm_group_label>
    <other_name>Tazarotene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAZORAC® (tazarotene) Cream 0.05%</intervention_name>
    <description>TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.</description>
    <arm_group_label>Reference</arm_group_label>
    <other_name>Tazarotene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (vehicle of the test product) to cover only the lesions with a thin film.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a definite clinical diagnosis of stable (at least 6 months) plaque psoriasis,
             involving at least 2% and no more than 20% of the body surface area (BSA) (not
             including the scalp and intertriginous areas)

          -  Have a minimum plaque elevation at the target lesion site of at least moderate
             severity (grade ≥ 3 on the Psoriasis Area Severity Index [PASI]). The most severe
             lesion at baseline should be identified as the target lesion

          -  Have an Investigator's Global Assessment (IGA) of disease severity of at least
             moderate (score ≥ 3) as an overall assessment of all lesions to be treated.

        Exclusion Criteria:

          -  A female subject who is pregnant, nursing, planning a pregnancy, or does not agree to
             use an acceptable form of birth control within the study participation period

          -  Have a current diagnosis of unstable forms of psoriasis in the treatment area,
             including pustular, guttate, exfoliative or erythrodermic psoriasis

          -  Have a history of psoriasis unresponsive to topical treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela C. Kaplan</last_name>
    <role>Study Director</role>
    <affiliation>Fougera Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Sweetwater</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fougera Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <results_first_submitted>July 30, 2018</results_first_submitted>
  <results_first_submitted_qc>July 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 29, 2018</results_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Tazarotene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02886702/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02886702/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>At Visit 1, eligible subjects were randomized to the Test, Reference or Placebo product in a 1:1:1 ratio using an interactive response technology (IRT) system.</recruitment_details>
      <pre_assignment_details>927 subjects were screened for study participation, 855 subjects were randomized and included in the statistical analyses.
29 investigative sites (one with two locations) randomized subjects into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Test</title>
          <description>Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)</description>
        </group>
        <group group_id="P2">
          <title>Reference</title>
          <description>TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="284"/>
                <participants group_id="P2" count="286"/>
                <participants group_id="P3" count="285"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent-to Treat (mITT)</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="266"/>
                <participants group_id="P3" count="275"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-Protocol Population (PP)</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="209"/>
                <participants group_id="P3" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="236"/>
                <participants group_id="P2" count="235"/>
                <participants group_id="P3" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Significant Worsening of Condition</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test</title>
          <description>Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)</description>
        </group>
        <group group_id="B2">
          <title>Reference</title>
          <description>TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="284"/>
            <count group_id="B2" value="286"/>
            <count group_id="B3" value="285"/>
            <count group_id="B4" value="855"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Started (Safety Population)</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="14.4"/>
                    <measurement group_id="B2" value="53.7" spread="14.2"/>
                    <measurement group_id="B3" value="52.7" spread="14.2"/>
                    <measurement group_id="B4" value="53.3" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Started (Safety Population)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="426"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Started (Safety Population)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="514"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Success Assessed by IGA</title>
        <description>Proportion of subjects with treatment success (defined as none, minimal or mild disease, a score of 0, 1 or 2 within the treatment area) on the &quot;Investigator's Global Assessment of Disease Severity&quot; (IGA) at the Week 12 visit (Day 85 ± 4 days, End of Study).</description>
        <time_frame>Week 12</time_frame>
        <population>mITT for superiority versus placebo, PP for equivalence versus Reference</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)</description>
          </group>
          <group group_id="O2">
            <title>Reference</title>
            <description>TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Success Assessed by IGA</title>
          <description>Proportion of subjects with treatment success (defined as none, minimal or mild disease, a score of 0, 1 or 2 within the treatment area) on the &quot;Investigator's Global Assessment of Disease Severity&quot; (IGA) at the Week 12 visit (Day 85 ± 4 days, End of Study).</description>
          <population>mITT for superiority versus placebo, PP for equivalence versus Reference</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8"/>
                    <measurement group_id="O2" value="63.2"/>
                    <measurement group_id="O3" value="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>90% confidence interval on the difference between the proportions to be within [-20%, +20%].</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-12.6</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Last Observation Carried Forward (LOCF) for missing efficacy values</non_inferiority_desc>
            <p_value>0.3520</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by clinical site</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Severity None or Minimal on IGA</title>
        <description>Proportion of subjects with none or minimal disease, a score of 0 or 1 on the IGA at the Week 12 visit (Day 85 ± 4 days, End of Study).</description>
        <time_frame>Week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)</description>
          </group>
          <group group_id="O2">
            <title>Reference</title>
            <description>TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Severity None or Minimal on IGA</title>
          <description>Proportion of subjects with none or minimal disease, a score of 0 or 1 on the IGA at the Week 12 visit (Day 85 ± 4 days, End of Study).</description>
          <population>mITT</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5"/>
                    <measurement group_id="O2" value="22.6"/>
                    <measurement group_id="O3" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8105</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by clinical site</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0613</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by clinical site</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Site Plaque Elevation, Scaling and Erythema Scores of Less Than or Equal to 1 on the PASI</title>
        <description>Proportion of subjects with target site plaque elevation, scaling and erythema scores of less than or equal to 1 (Clear or Almost Clear) on the Psoriasis Area Severity Index (PASI) at the Week 12 visit (Day 85 ± 4 days, End of Study).</description>
        <time_frame>Week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Test</title>
            <description>Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)</description>
          </group>
          <group group_id="O2">
            <title>Reference</title>
            <description>TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
          </group>
        </group_list>
        <measure>
          <title>Target Site Plaque Elevation, Scaling and Erythema Scores of Less Than or Equal to 1 on the PASI</title>
          <description>Proportion of subjects with target site plaque elevation, scaling and erythema scores of less than or equal to 1 (Clear or Almost Clear) on the Psoriasis Area Severity Index (PASI) at the Week 12 visit (Day 85 ± 4 days, End of Study).</description>
          <population>mITT</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="22.2"/>
                    <measurement group_id="O3" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by clinical site</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0712</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratified by clinical site</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to approximately 85 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test</title>
          <description>Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)</description>
        </group>
        <group group_id="E2">
          <title>Reference</title>
          <description>TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="286"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Application site erosion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="284"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="286"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Fougera' agreements with its investigators may vary. However, Fougera does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela C Kaplan</name_or_title>
      <organization>Fougera Pharmaceuticals Inc.</organization>
      <phone>631-659-2256</phone>
      <email>angela.kaplan@sandoz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

